Stockscreener 앱 받기
18.23
4.17%
0.73
시간 외 거래:
18.23
전일 마감가:
$17.50
열려 있는:
$17.53
하루 거래량:
944.19K
Relative Volume:
0.78
시가총액:
$1.46B
수익:
$123.67M
순이익/손실:
$-38.63M
주가수익비율:
-29.55
EPS:
-0.617
순현금흐름:
$-27.50M
1주 성능:
+6.48%
1개월 성능:
+13.80%
6개월 성능:
+64.09%
1년 성능:
+311.51%
1일 변동 폭
$17.35
$18.50
1주일 범위
$16.89
$18.50
52주 변동 폭
$3.51
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
18.23 | 1.40B | 123.67M | -38.63M | -27.50M | -0.617 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Warmuth, Monte Rosa Therapeutics CEO, sells $141k in Glue stock - Investing.com Australia
Markus Warmuth sells 5,466 shares of GLUE (NASDAQ: GLUE) under Rule 144 - Stock Titan
Edmund Dunn files Form 144 reporting GLUE (NASDAQ: GLUE) common stock sales - Stock Titan
Insider Sell: Philip Nickson Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
Monte Rosa Therapeutics Insider Sells Over $100K in Shares - National Today
Philip Nickson Sells 5,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock - MarketBeat
Insider at Monte Rosa Therapeutics (GLUE) sells 5,845 shares - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
26,117 GLUE shares reported for sale (NASDAQ: GLUE) in Form 144 - Stock Titan
GLUE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Performance Recap: Is Monte Rosa Therapeutics Inc forming a bullish divergenceCEO Change & Detailed Earnings Play Strategies - baoquankhu1.vn
Aug Momentum: Is Monte Rosa Therapeutics Inc subject to activist investor interest2026 Recap & Safe Entry Point Alerts - baoquankhu1.vn
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE) grants equity awards to accounting chief - Stock Titan
Monte Rosa Therapeutics (NASDAQ: GLUE) officer reports stock and option holdings in Form 3 - Stock Titan
Investor Mood: How sensitive is Monte Rosa Therapeutics Inc to inflationTrend Reversal & Proven Capital Preservation Tips - baoquankhu1.vn
Analysts’ Top Healthcare Picks: Nurix Therapeutics (NRIX), Immunocore Holdings (IMCR) - The Globe and Mail
Quarterly Earnings: How sensitive is Monte Rosa Therapeutics Inc to inflation2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Gainers Report: What are the risks of holding Monte Rosa Therapeutics IncRisk Management & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aug Patterns: Can Monte Rosa Therapeutics Inc lead its sector in growth2026 Technicals & Weekly Momentum Picks - baoquankhu1.vn
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)? - simplywall.st
Trading Recap: Will Monte Rosa Therapeutics Inc benefit from AI trends2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement - Sahm
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Monte Rosa Therapeutics urges new pathways for the next generation of scientists - Traders Union
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Aug Ideas: Can Monte Rosa Therapeutics Inc lead its sector in growthQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
Can Monte Rosa Therapeutics Inc lead its sector in growthTrade Ideas & Long-Term Capital Growth Ideas - baoquankhu1.vn
Breakouts Watch: How sensitive is Monte Rosa Therapeutics Inc to inflationQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Big Picture: Does Monte Rosa Therapeutics Inc stock have upside surprise potentialRate Hike & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story - Yahoo Finance
Wall Street Zen Downgrades Monte Rosa Therapeutics to 'Sell' - National Today
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Risks Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceQuarterly Earnings Summary & Verified Technical Signals - baoquankhu1.vn
Does Monte Rosa Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Lantheus (LNTH) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00 - MarketBeat
Monte Rosa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim - TipRanks
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative - simplywall.st
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses - AlphaStreet
Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics Reports Positive Clinical Data and $345M Financing, Advancing Multiple Phase 2 Trials into 2029 - Minichart
Is Monte Rosa Therapeutics Inc stock a hidden gem2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Monte Rosa Therapeutics (GLUE) reports Q4 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% - AlphaStreet
Monte Rosa’s QuEEN™ Discovery Engine: AI-Driven Molecular Glue Degraders Targeting Undruggable Proteins in Biotechnology 4145465158 - Minichart
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):